Project Grant R01HL181987
- This Project Grant award, titled "Genetic Ancestry Effects on Molecular and Complex Traits in TOPMed", is funded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The $804,982 award, effective July 25, 2025 through April 30, 2029, supports research to leverage the Trans-Omics for Precision Medicine (TOPMed) project data to understand how race, ethnicity, and genetic ancestry contribute to complex...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA program 93.837 Cardiovascular Diseases Research is providing $807,948 to support a study on the genetics of left ventricular hypertrophy (LVH) and associated cardiac phenotypes. The primary awardee, The Medical College of Wisconsin, Inc. (MCW), will utilize whole genome sequencing data from the NHLBI TOPMed program to conduct association analyses and identify genetic variants related to LVH....
- The National Heart, Lung, and Blood Institute (NHLBI) has awarded a $126,309 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Children's Hospital Medical Center in Cincinnati, Ohio. This 2-year research project, awarded on June 16, 2025, aims to characterize the functional role of a novel cardiac and adipose-enriched microprotein called NRAC and its involvement in lipid droplet biogenesis and lipid metabolism within the cardiovascular system. The research will...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $817,208 to The Broad Institute, Inc. to investigate the genetic basis and underlying mechanisms of heart failure. The research leverages high-throughput cellular analysis techniques, including cell painting and Perturb-seq, to functionally characterize genetic variants associated with heart failure risk. The goal is to rapidly...
- This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will provide $136,449 to The Regents of the University of California, doing business as the University of California, Berkeley, to evaluate the role of human obesity genes in specific neuronal populations using a CRISPR-based approach. The research aims to determine how genetic variation...
- The University of Washington was awarded a $805,464 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) to conduct research on the genetic and environmental contributions to obesity pathogenesis. The award, effective August 1, 2025 through April 30, 2030, will focus on using rodent models and epidemiologic/twin study approaches to: 1) test genetic risk factors for hypothalamic gliosis, and 2) test environmental risk factors for obesity and...
- This federal Project Grant award of $169,020.00 was provided by the National Heart Lung and Blood Institute (NHLBI), which operates under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research at the University of Pennsylvania investigating the impact of obesity and diabetes on coronary microvascular defects in heart failure with preserved ejection fraction (HFpEF). The research will use an animal model of HFpEF to compare the temporal progression...
- This federal Project Grant award of $1,119,410.00 was provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports a multi-disciplinary research initiative to investigate longitudinal changes in DNA methylation (LC-DNAM) and its relationship to cardiovascular disease (CVD) risk factors and outcomes across four large population-based cohort studies - ARIC, CARDIA, FHS, and MESA. The research aims to: 1)...
- This federal Project Grant award of $777,016.00 from the National Heart Lung and Blood Institute (CFDA Program 93.837 - Cardiovascular Diseases Research) supports research to functionally characterize genes and genetic variants associated with hypoplastic heart syndrome (HHS) in the Drosophila model organism. The University of Maryland, Baltimore is the primary awardee and will apply a high-throughput "gene replacement" approach to validate 386 genetic variants linked to HHS,...
- This $734,722 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports a randomized controlled clinical trial to assess the impact of disclosing systolic blood pressure polygenic risk scores on blood pressure control, healthy lifestyle adherence, and cardiometabolic health among 300 hypertensive adults aged 18-55 in the United States. The study aims to evaluate whether providing individuals with information about their...
This federal Project Grant award for $732,261 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to identify central obesity genes and validate their function using in vitro and in vivo models. The project aims to leverage large-scale, multi-ethnic genomic and multi-omic data from nine longitudinal studies in the NHLBI Trans-Omics for Precision Medicine (TOPMed) program to pinpoint target genes that influence biological pathways related to central obesity. The research will utilize expression and protein quantitative trait loci analyses, along with colocalization, Mendelian randomization, and Bayesian network approaches, to link central obesity GWAS variants to putative causal genes. The awarded institution, the University of Virginia, will validate the prioritized central obesity genes through cell-based and diet-induced mouse models. The project is expected to run from September 2025 through June 2029.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 9/19/25 | ||
| Not listed | $732.3k | 9/12/25 |